MedTrace Logo

Autologous Atrial Appendage Derived Cells in the Treatment of Heart Failure

NCT02672163 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-03-05

No results posted yet for this study

Summary

This study aims to evaluate the safety and clinical feasibility of epicardially delivered autologous atrial appendage micrografts in the treatment of heart failure. The micrografts consisting atrial-derived cells and their extracellular matrix, are placed on an infarction scar during CABG surgery.

Conditions

Interventions

PROCEDURE

CABG surgery

Elective CABG surgery

PROCEDURE

AADC therapy

Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet

Sponsors & Collaborators

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Ari Harjula, Prof · Heart and Lung Center, Helsinki University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02672163 on ClinicalTrials.gov